Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry.

IF 3.3 4区医学 Q2 ONCOLOGY

Breast Cancer : Targets and Therapy Pub Date : 2025-03-12 eCollection Date: 2025-01-01 DOI:10.2147/BCTT.S507189

Yi-Fang Tsai, Chih-Yi Hsu, Yun-Ning Chiu, Chi-Cheng Huang, Shih-Hsiang Chou, Yen-Shu Lin, Ta-Chung Chao, Chun-Yu Liu, Jen-Hwey Chiu, Ling-Ming Tseng

{"title":"Genetic Alterations in HER2-Positive and Equivocal Breast Cancer by Immunohistochemistry.","authors":"Yi-Fang Tsai, Chih-Yi Hsu, Yun-Ning Chiu, Chi-Cheng Huang, Shih-Hsiang Chou, Yen-Shu Lin, Ta-Chung Chao, Chun-Yu Liu, Jen-Hwey Chiu, Ling-Ming Tseng","doi":"10.2147/BCTT.S507189","DOIUrl":null,"url":null,"abstract":"Purpose: We aimed to identify genetic alterations in groups with different HER2 immunohistochemical (IHC) scores.Patients and methods: A total of 120 patients with HER2-positive breast cancers, including 89 cases with IHC 3+ tumors and 31 cases with IHC 2+ and positive for in situ hybridization (ISH) were enrolled. Molecular profiles were determined using Thermo Fisher TMO comprehensive assay on surgically removed tissues. All called variants were compared between IHC3+ and IHC2+/ISH+ groups by Fisher exact test.Results: There was a significantly higher sample frequency 94.4% (84/89) of ERBB2 amplification in IHC3+ group than that in IHC2+/ISH+ group 45.2% (14/31). By contrast, there was a significantly lower sample frequency of MYC_AMP_CNA 10.1% (9/89) and CCND3_AMP_CNA 0% (0/89) in IHC3+ group than those in IHC2+/ISH+ group with sample frequency 25.8% (8/31), and 9.7% (3/31), respectively.Conclusion: We conclude that HER2 IHC3+ tumors have higher frequency of ERBB2_ AMP_CNA and lower frequency of CCND3_ AMP_CNA and MYC_AMP_CNA than IHC2+/ISH+ tumors. These results provide therapeutic strategies in treatment of HER2-positive breast cancer.","PeriodicalId":9106,"journal":{"name":"Breast Cancer : Targets and Therapy","volume":"17 ","pages":"253-263"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911235/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer : Targets and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/BCTT.S507189","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We aimed to identify genetic alterations in groups with different HER2 immunohistochemical (IHC) scores.

Patients and methods: A total of 120 patients with HER2-positive breast cancers, including 89 cases with IHC 3+ tumors and 31 cases with IHC 2+ and positive for in situ hybridization (ISH) were enrolled. Molecular profiles were determined using Thermo Fisher TMO comprehensive assay on surgically removed tissues. All called variants were compared between IHC3+ and IHC2+/ISH+ groups by Fisher exact test.

Results: There was a significantly higher sample frequency 94.4% (84/89) of ERBB2 amplification in IHC3+ group than that in IHC2+/ISH+ group 45.2% (14/31). By contrast, there was a significantly lower sample frequency of MYC_AMP_CNA 10.1% (9/89) and CCND3_AMP_CNA 0% (0/89) in IHC3+ group than those in IHC2+/ISH+ group with sample frequency 25.8% (8/31), and 9.7% (3/31), respectively.

Conclusion: We conclude that HER2 IHC3+ tumors have higher frequency of ERBB2_ AMP_CNA and lower frequency of CCND3_ AMP_CNA and MYC_AMP_CNA than IHC2+/ISH+ tumors. These results provide therapeutic strategies in treatment of HER2-positive breast cancer.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer : Targets and Therapy ONCOLOGY-

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

16 weeks